“Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis”, J of Skin, vol. 7, no. 6, p. s276, Nov. 2023, doi: 10.25251/skin.7.supp.276.